|Mr. Thomas A. West||Pres, CEO & Director||908.97k||N/A||1964|
|Mr. Richard A. Meier||Exec. VP & CFO||621.76k||N/A||1960|
|Mr. Patrick A. Broderick||Exec. VP, Gen. Counsel & Corp. Sec.||138.46k||N/A||1959|
|Ms. Reyna M. Fernandez||Chief Human Resource Officer||115.96k||N/A||N/A|
|Mr. Drake R. Parker||Advisor of Strategic Initiatives||N/A||N/A||1964|
Intersect ENT, Inc. operates as an ear, nose, and throat (ENT) medical technology company in the United States. The company offers PROPEL and PROPEL Mini, which are steroid releasing implants for patients undergoing sinus surgery to treat chronic sinusitis; and PROPEL Contour, a steroid releasing implant to frontal and maxillary sinus ostia, or openings, of the dependent sinuses. It also provides SINUVA, a steroid releasing implant for the treatment of patients in the physician office setting; VENSURE Navigable and Stand-alone balloon, a sterile and single-use device, used to access and treat frontal, sphenoid sinus, and maxillary ostia in adults using a trans-nasal approach; and CUBE Navigation System, a virtual guidance platform for high precision ENT and ENT related skull-base surgeries. The company was formerly known as Sinexus, Inc. and changed its name to Intersect ENT, Inc. in November 2009. Intersect ENT, Inc. was incorporated in 2003 and is headquartered in Menlo Park, California.
Intersect ENT, Inc.’s ISS Governance QualityScore as of September 26, 2021 is 6. The pillar scores are Audit: 7; Board: 1; Shareholder Rights: 6; Compensation: 9.